Published in J Clin Cell Immunol on May 30, 2014
Heme Oxygenases in Cardiovascular Health and Disease. Physiol Rev (2016) 0.82
Features of an altered AMPK metabolic pathway in Gilbert's Syndrome, and its role in metabolic health. Sci Rep (2016) 0.76
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A (2013) 16.74
Septic shock. Lancet (2005) 6.67
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood (2011) 5.61
Stabilization of mRNA expression in whole blood samples. Clin Chem (2002) 3.23
The role of the anaphylatoxins in health and disease. Mol Immunol (2009) 2.95
Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med (1993) 2.84
Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation (2006) 2.18
Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood) (2003) 2.16
Neonatal hyperbilirubinemia. N Engl J Med (2001) 2.15
Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med (1997) 2.00
Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol (2011) 1.98
Molecular biology of inflammation and sepsis: a primer. Crit Care Med (2009) 1.86
Kinetics of TNF, IL-6, and IL-8 gene expression in LPS-stimulated human whole blood. Biochem Biophys Res Commun (1991) 1.86
INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med (1996) 1.73
Role of Toll-like receptors in the development of sepsis. Shock (2008) 1.57
Current trends in inflammatory and immunomodulatory mediators in sepsis. J Leukoc Biol (2012) 1.52
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS (2007) 1.52
Biliverdin administration protects against endotoxin-induced acute lung injury in rats. Am J Physiol Lung Cell Mol Physiol (2005) 1.49
Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J (2005) 1.49
Interleukin-8. Crit Care Med (2005) 1.46
Biliverdin protects the functional integrity of a transplanted syngeneic small bowel. Gastroenterology (2004) 1.39
Biliverdin therapy protects rat livers from ischemia and reperfusion injury. Hepatology (2004) 1.37
Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both. Am J Transplant (2005) 1.36
Biliverdin, a natural product of heme catabolism, induces tolerance to cardiac allografts. FASEB J (2004) 1.28
New approaches to the study of sepsis. EMBO Mol Med (2012) 1.27
Cell surface biliverdin reductase mediates biliverdin-induced anti-inflammatory effects via phosphatidylinositol 3-kinase and Akt. J Biol Chem (2009) 1.20
Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients. Cochrane Database Syst Rev (2012) 1.18
Biliverdin inhibits activation of NF-kappaB: reversal of inhibition by human biliverdin reductase. Int J Cancer (2007) 1.17
Bilirubin inhibits iNOS expression and NO production in response to endotoxin in rats. Hepatology (2004) 1.17
Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. Atherosclerosis (2007) 1.16
Biliverdin protects against polymicrobial sepsis by modulating inflammatory mediators. Am J Physiol Gastrointest Liver Physiol (2006) 1.12
Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status in Gilbert syndrome. Free Radic Biol Med (2012) 1.06
Inflammatory signalling pathways involved in astroglial activation by unconjugated bilirubin. J Neurochem (2006) 1.02
Biliverdin inhibits Toll-like receptor-4 (TLR4) expression through nitric oxide-dependent nuclear translocation of biliverdin reductase. Proc Natl Acad Sci U S A (2011) 1.02
Bilirubin and beyond: a review of lipid status in Gilbert's syndrome and its relevance to cardiovascular disease protection. Prog Lipid Res (2012) 1.01
TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2. Eur J Immunol (2011) 1.00
Bilirubin in clinical practice: a review. Liver Int (2008) 0.99
Bile pigment pharmacokinetics and absorption in the rat: therapeutic potential for enteral administration. Br J Pharmacol (2011) 0.95
Seasonal variation in whole blood cytokine production after LPS stimulation in normal individuals. Cytokine (2003) 0.95
Inflammatory responses induced by lipopolysaccharide are amplified in primary human monocytes but suppressed in macrophages by complement protein C5a. J Immunol (2013) 0.94
Arylhydrocarbon receptor activation in NCI-H441 cells and C57BL/6 mice: possible mechanisms for lung dysfunction. Am J Respir Cell Mol Biol (2009) 0.94
Single bolus injection of bilirubin improves the clinical outcome in a mouse model of endotoxemia. Shock (2007) 0.93
Bilirubin can induce tolerance to islet allografts. Endocrinology (2005) 0.90
Inflammation, leukocytes and menstruation. Rev Endocr Metab Disord (2012) 0.90
XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases. MAbs (2011) 0.90
Effects of bilirubin on neutrophil responses in newborn infants. Neonatology (2012) 0.89
Haem catabolism: a novel modulator of inflammation in Gilbert's syndrome. Eur J Clin Invest (2013) 0.89
Role of the aryl hydrocarbon receptor (AhR) in lung inflammation. Semin Immunopathol (2013) 0.88
Cytokine modulation in experimental endotoxemia: characterization of an ex vivo whole blood model. Eur Surg Res (2000) 0.87
Bilirubin produces apoptosis in cultured bovine brain endothelial cells. Brain Res (2002) 0.87
Hematologic changes in sepsis and their therapeutic implications. Semin Respir Crit Care Med (2004) 0.86
Differential regulation of monocyte/macrophage cytokine production by pressure. Am J Surg (2005) 0.86
Effects of biliverdin administration on acute lung injury induced by hemorrhagic shock and resuscitation in rats. PLoS One (2013) 0.86
The molecular basis for the immunomodulatory activities of unconjugated bilirubin. Int J Biochem Cell Biol (2013) 0.85
Apoptosis in murine hepatoma hepa 1c1c7 wild-type, C12, and C4 cells mediated by bilirubin. Mol Pharmacol (2002) 0.85
Neonatal hyperbilirubinemia--what are the risks? N Engl J Med (2006) 0.85
Interleukin 8 production in whole blood assays: Is interleukin 10 responsible for the downregulation observed in sepsis? Cytokine (2000) 0.85
Lipopolysaccharide-stimulated whole blood cytokine production does not predict the inflammatory response in human endotoxemia. Innate Immun (2009) 0.84
Time course-dependent changes in the transcriptome of human skeletal muscle during recovery from endurance exercise: from inflammation to adaptive remodeling. J Appl Physiol (1985) (2013) 0.82
CO and bilirubin inhibit doxorubicin-induced cardiac cell death. Immunopharmacol Immunotoxicol (2009) 0.82
Exogenous biliverdin improves the function of lung grafts from brain dead donors in rats. Transplant Proc (2010) 0.81
Biliverdin modulates the expression of C5aR in response to endotoxin in part via mTOR signaling. Biochem Biophys Res Commun (2014) 0.80
Contributions of the Ah receptor to bilirubin homeostasis and its antioxidative and atheroprotective functions. Biol Chem (2010) 0.79
The use of real time rtPCR to quantify inflammatory mediator expression in leukocytes from patients with severe sepsis. Anaesth Intensive Care (2004) 0.79
Biliverdin protects against liver ischemia reperfusion injury in swine. PLoS One (2013) 0.79
Recipient hyperbilirubinaemia protects cardiac graft in rat heterotopic heart transplantation. Eur J Cardiothorac Surg (2013) 0.76
Biliverdin modulates the expression of C5aR in response to endotoxin in part via mTOR signaling. Biochem Biophys Res Commun (2014) 0.80